Our study implied that the DKK1–PI3K–AKT signaling pathway may be a potential predictive index and therapeutic target for HNSCC patients with PNI and that MK2206 may be a potential therapeutic target drug for HNSCC patients with high DKK1 expression. Here, AKT1 is linked to head and neck squamous cell carcinoma.